



Insecticide-Treated Bed Nets with Piperonyl Butoxide in Pyrethroid-Resistant *Anopheles* Populations

Arionget Jemima

Department of Pharmacoepidemiology Kampala International University Uganda

Email: jemima.arionget@studwc.kiu.ac.ug

ABSTRACT

Insecticide-treated bed nets represented a cornerstone intervention in malaria vector control, contributing significantly to reduced transmission across endemic regions. However, widespread pyrethroid resistance in *Anopheles* mosquito populations threatened to undermine these gains, driven primarily by enhanced metabolic detoxification through cytochrome P450 monooxygenases and target site mutations in voltage-gated sodium channels. This review examined the biochemical mechanisms underlying pyrethroid resistance in *Anopheles* vectors and evaluated the efficacy of piperonyl butoxide synergist-treated bed nets as a countermeasure strategy in resistance management programs. A comprehensive literature review was conducted, analyzing peer-reviewed publications from 2010 to 2025, focusing on pyrethroid resistance mechanisms, cytochrome P450 biochemistry, piperonyl butoxide pharmacology, and field trial outcomes of synergist-treated nets. Pyrethroid resistance manifested through multiple biochemical pathways, with cytochrome P450-mediated metabolic resistance representing the predominant mechanism in most African *Anopheles* populations. Piperonyl butoxide functioned as a mechanism-based cytochrome P450 inhibitor, forming stable metabolic intermediate complexes that restored pyrethroid susceptibility in metabolically resistant mosquitoes. Field trials demonstrated that piperonyl butoxide-treated nets provide superior epidemiological protection compared to standard pyrethroid-only nets in areas with confirmed metabolic resistance, reducing malaria prevalence and clinical incidence. Piperonyl butoxide-treated bed nets represented an evidence-based tool for maintaining vector control effectiveness in pyrethroid-resistant settings, though sustained impact required integration within comprehensive resistance management strategies incorporating surveillance, rotation policies, and novel insecticide classes.

Keywords: Pyrethroid resistance, Piperonyl butoxide, Cytochrome P450, *Anopheles* vectors, Insecticide-treated nets.

INTRODUCTION

Malaria remains among the most significant parasitic diseases globally, with more than 241 million cases and 627,000 deaths reported in 2020, predominantly affecting sub-Saharan African populations [1,2]. Vector control interventions, particularly insecticide-treated bed nets and indoor residual spraying, have contributed substantially to the 27% reduction in malaria incidence observed between 2000 and 2020 [3]. Pyrethroid insecticides dominate these interventions due to their rapid knockdown effects, favorable mammalian safety profiles, and economic feasibility for large-scale deployment [4]. However, the emergence and spread of pyrethroid resistance in *Anopheles* mosquito populations across malaria-endemic regions threatens to reverse these public health achievements [5]. Resistance mechanisms involve complex biochemical adaptations, primarily enhanced metabolic detoxification through upregulated cytochrome P450 monooxygenases and target site insensitivity caused by mutations in voltage-gated sodium channel genes [6]. These mechanisms compromise insecticide efficacy, potentially reducing the protective effect of standard pyrethroid-treated nets and undermining transmission control efforts [7]. The development of next-generation insecticide-treated nets incorporating piperonyl butoxide, a synergist that inhibits cytochrome P450 enzymes, represents a promising strategy for restoring insecticide susceptibility in metabolically resistant mosquito populations [8]. This review systematically examines the biochemical foundations of pyrethroid resistance mechanisms in *Anopheles* vectors, elucidates the molecular pharmacology of piperonyl butoxide as a cytochrome P450 inhibitor, analyzes field trial evidence demonstrating epidemiological impact of synergist-treated

<https://rijournals.com/biological-and-applied-science/>

nets, discusses resistance surveillance methodologies informing deployment strategies, and evaluates policy implications for integrating these tools within comprehensive insecticide resistance management frameworks. Understanding these interconnected elements proves essential for maintaining effective vector control in the evolving landscape of insecticide resistance.

BIOCHEMICAL MECHANISMS OF PYRETHROID RESISTANCE

Pyrethroid Mode of Action and Target Site

Pyrethroid insecticides exert neurotoxic effects by binding to voltage-gated sodium channels in neuronal membranes, prolonging channel opening and disrupting normal action potential propagation. This results in repetitive neuronal firing, paralysis, and ultimately mortality in susceptible insects. Type I pyrethroids lacking an alpha-cyano group produce tremor syndrome, while Type II pyrethroids containing this moiety cause choreoathetosis and salivation, reflecting differences in binding kinetics and downstream neurophysiological effects [9].

The molecular target comprises a transmembrane protein complex with four homologous domains, each containing six transmembrane segments, forming the ion-conducting pore and voltage-sensing apparatus [10]. Pyrethroids bind within the inner cavity of the channel, interacting with residues in the S5 and S6 segments, stabilizing the open conformation and preventing channel inactivation [11]. This prolonged depolarization disrupts normal synaptic transmission, overwhelming the insect nervous system.

Target Site Resistance: Knockdown Resistance Mutations

Target site insensitivity, commonly termed knockdown resistance, arises from nonsynonymous mutations in the voltage-gated sodium channel gene that reduce pyrethroid binding affinity without substantially compromising normal channel function. The most prevalent mutations occur at position 1014 in domain II segment 6, with leucine to phenylalanine (L1014F) substitution predominating in West African *Anopheles gambiae* populations and leucine to serine (L1014S) substitution prevalent in East African populations. These amino acid replacements alter the three-dimensional structure of the pyrethroid binding pocket, reducing ligand affinity and thereby conferring resistance [12].

Additional mutations at position 1575 in domain III, particularly the valine to methionine substitution (N1575Y), enhance resistance levels when present alongside L1014F mutations, demonstrating epistatic interactions between resistance alleles [13]. Biochemical studies using heterologous expression systems reveal that dual mutations reduce pyrethroid potency by 10 to 100 fold compared to wild-type channels, with the magnitude varying among pyrethroid compounds and structural classes [14]. Despite these substantial effects, knockdown resistance mutations alone typically confer moderate resistance levels insufficient to completely negate insecticide efficacy under operational conditions [15].

Metabolic Resistance: Cytochrome P450 Monooxygenases

Metabolic resistance through enhanced insecticide detoxification represents the predominant mechanism observed in African *Anopheles* populations, frequently occurring alongside target site mutations in field populations [16]. Cytochrome P450 monooxygenases constitute a diverse superfamily of heme-containing enzymes catalyzing oxidative metabolism of xenobiotics, including insecticides, through reactions involving molecular oxygen and electron transfer from NADPH cytochrome P450 reductase [17].

The catalytic cycle begins with substrate binding to the oxidized ferric heme center, followed by reduction to the ferrous state through electron transfer from NADPH via the flavoprotein reductase [18]. Molecular oxygen then binds, undergoes further reduction and protonation, generating a highly reactive ferryl-oxo species that abstracts hydrogen from the substrate or inserts oxygen into carbon-hydrogen bonds. These oxidative transformations typically increase insecticide polarity, facilitating excretion and reducing target site accumulation.

Multiple cytochrome P450 genes demonstrate transcriptional upregulation in pyrethroid-resistant *Anopheles* populations, with CYP6P3, CYP6M2, CYP6P4, and CYP9K1 showing particularly strong associations with resistance phenotypes across sub-Saharan Africa [19]. Functional validation using transgenic *Drosophila melanogaster* expressing individual *Anopheles* P450 enzymes confirms their capacity to metabolize pyrethroids in vivo, establishing causal relationships between enzyme expression and resistance [20]. Biochemical studies demonstrate that these enzymes catalyze pyrethroid hydroxylation at multiple positions, generating less toxic metabolites that do not effectively bind voltage-gated sodium channels.

Carboxylesterases and Glutathione S-Transferases

While cytochrome P450 enzymes dominate metabolic resistance in most settings, carboxylesterases and glutathione S-transferases contribute to resistance phenotypes in certain populations. Carboxylesterases hydrolyze the ester linkage present in pyrethroid structures, though this mechanism appears less prevalent than P450-mediated oxidation in field populations. Glutathione S-transferases catalyze conjugation of glutathione to electrophilic substrates, potentially detoxifying reactive pyrethroid metabolites or oxidative stress byproducts generated during insecticide exposure [21].

<https://rijournals.com/biological-and-applied-science/>

Epsilon class glutathione S-transferases, particularly GSTe2, show elevated expression in some resistant populations and demonstrate dehydrochlorination activity against DDT, though their direct role in pyrethroid metabolism remains less established than for organochlorines [22]. The relative contribution of these enzyme families varies geographically and among Anopheles species, highlighting the biochemical complexity and evolutionary plasticity of resistance mechanisms [23].

PIPERONYL BUTOXIDE: MECHANISM AND PHARMACOLOGY

Chemical Structure and Cytochrome P450 Inhibition

Piperonyl butoxide is a methylenedioxyphenyl compound originally developed in the 1940s as a synergist to enhance pyrethrin insecticide efficacy. The molecule comprises a benzodioxole ring system connected through a propyl ether linkage to a branched alkoxy side chain, structural features critical for cytochrome P450 binding and inhibitory activity. Piperonyl butoxide functions as a mechanism-based inhibitor, also termed a suicide substrate, undergoing initial enzymatic oxidation that generates reactive intermediates, forming stable complexes with the P450 heme prosthetic group [24].

The inhibition mechanism involves cytochrome P450-catalyzed oxidation of the methylenedioxyphenyl moiety, generating a carbene intermediate that forms a stable metabolic intermediate complex with the reduced ferrous heme iron. This complex exhibits characteristic spectral properties with absorption maxima at 455 nanometers, distinct from the native ferrous-carbon monoxide complex at 450 nanometers. The metabolic intermediate complex demonstrates exceptional stability, effectively sequestering the enzyme in a catalytically inactive state for extended periods, thereby preventing pyrethroid metabolism.

Selectivity for Insect Cytochrome P450 Enzymes

Piperonyl butoxide demonstrates preferential inhibition of insect cytochrome P450 enzymes compared to mammalian isoforms, contributing to its favorable safety profile in human populations. This selectivity reflects differences in P450 active site architecture, substrate recognition sequences, and redox partner interactions between insect and mammalian enzyme systems [25]. Studies measuring inhibitory potency across diverse P450 isoforms reveal that piperonyl butoxide inhibits insect P450s at micromolar concentrations while requiring substantially higher concentrations to affect human liver P450 enzymes involved in drug metabolism [26].

The methylenedioxyphenyl pharmacophore appears critical for insect P450 selectivity, as structural modifications to this moiety dramatically alter inhibition profiles. Biochemical investigations demonstrate that piperonyl butoxide preferentially inhibits Anopheles CYP6 family enzymes implicated in pyrethroid resistance, including CYP6P3 and CYP6M2, while showing reduced activity against CYP4 family enzymes and esterases [27]. This mechanism specificity proves advantageous for resistance management, as it directly targets the predominant metabolic resistance pathway without broadly suppressing all detoxification systems.

Pharmacokinetics in Mosquito Vectors

Following contact with piperonyl butoxide-treated surfaces, mosquitoes absorb the synergist through tarsal penetration, with subsequent distribution throughout tissues, including the nervous system. Peak tissue concentrations occur within 1 to 2 hours post-exposure, with persistence depending on dose, formulation, and environmental conditions. The extended residence time on treated nets ensures sufficient exposure to achieve cytochrome P450 inhibition before mosquitoes encounter pyrethroid insecticides incorporated within the same netting material [28].

Studies using radiolabeled piperonyl butoxide demonstrate that absorbed synergist accumulates preferentially in lipid-rich tissues where cytochrome P450 enzymes reside, optimizing inhibitory effects at the relevant biochemical sites [29]. The sequential exposure paradigm, where mosquitoes first contact piperonyl butoxide followed by pyrethroid within minutes, proves essential for efficacy, as the synergist requires time to establish metabolic intermediate complexes before insecticide metabolism can occur [30].

FIELD TRIAL EVIDENCE AND EPIDEMIOLOGICAL IMPACT

Efficacy Studies in Resistant Populations

Multiple large-scale cluster randomized controlled trials have evaluated the epidemiological impact of piperonyl butoxide-treated bed nets compared to standard pyrethroid-only nets in areas with confirmed metabolic resistance [31]. The largest trial, conducted across Tanzania with over 4,400 participants, demonstrated that piperonyl butoxide nets reduced malaria prevalence by 44% compared to standard nets in areas where mosquitoes exhibited high-intensity pyrethroid resistance [50]. This protective effect exceeded that observed with standard nets, which showed no significant impact in the same high-resistance setting [32].

Similar trials in Uganda revealed that piperonyl butoxide nets reduced clinical malaria incidence by 27% and reduced anemia prevalence by 17% in children under five years compared to standard pyrethroid nets [33]. Entomological monitoring within these trials documented higher mosquito mortality rates on piperonyl butoxide nets compared to standard nets when tested with local resistant populations, confirming that enhanced epidemiological protection corresponded with improved entomological efficacy [34].

<https://rijournals.com/biological-and-applied-science/>

Biochemical assays measuring cytochrome P450 activity in mosquitoes collected from trial sites demonstrated strong correlations between P450 expression levels and the magnitude of added benefit from piperonyl butoxide nets [35]. In settings with low P450-mediated resistance, piperonyl butoxide nets showed similar performance to standard nets, whereas in high P450 resistance settings, the synergist provided substantial added value [36]. These findings validate the mechanistic hypothesis that piperonyl butoxide overcomes metabolic resistance by inhibiting pyrethroid-detoxifying enzymes [37].

Durability and Wash Resistance

The operational effectiveness of piperonyl butoxide-treated nets depends critically on retention of both pyrethroid and synergist following repeated washing and extended field use [38]. Laboratory wash resistance testing following World Health Organization protocols demonstrates that piperonyl butoxide remains detectable on netting materials after 20 standardized washes, though concentrations decline more rapidly than incorporated pyrethroids [39]. Field durability studies tracking nets over three years of household use reveal that bioassay efficacy against resistant mosquitoes gradually diminishes, though piperonyl butoxide nets maintain superior performance compared to standard nets throughout the monitoring period.

The differential wash resistance between synergist and insecticide potentially creates windows where piperonyl butoxide depletion occurs while pyrethroids persist, reducing synergistic effects [40]. Manufacturers have optimized coating formulations to improve piperonyl butoxide retention, employing polymer matrices and binding technologies that enhance durability. Recent products demonstrate improved retention profiles, though continued monitoring remains essential to ensure operational longevity matches laboratory predictions [41].

Cost-Effectiveness Analysis

Economic evaluations comparing piperonyl butoxide nets to standard pyrethroid nets incorporate multiple factors, including procurement costs, operational lifespan, epidemiological impact, and healthcare expenditure averted [42]. While piperonyl butoxide nets cost approximately 30 to 40% more than standard nets, the enhanced protective effect in resistant settings improves cost-effectiveness ratios [43]. Modeling studies from Tanzania estimate that piperonyl butoxide nets achieve incremental cost-effectiveness ratios of \$27 to \$34 per disability adjusted life year averted in high-resistance areas, falling well below commonly accepted willingness-to-pay thresholds [44].

These favorable economic profiles depend critically on deploying piperonyl butoxide nets in appropriate settings where metabolic resistance predominates [45]. In areas with predominantly target site resistance or susceptible mosquito populations, the added cost of synergist nets provides minimal incremental benefit, reducing cost effectiveness [46]. This context dependency emphasizes the importance of resistance surveillance to guide deployment decisions and optimize resource allocation [47].

RESISTANCE SURVEILLANCE AND DEPLOYMENT STRATEGIES

Biochemical and Molecular Diagnostic Approaches

Effective deployment of piperonyl butoxide-treated nets requires robust surveillance systems capable of characterizing resistance mechanisms in local mosquito populations [48]. Standard World Health Organization susceptibility bioassays measure mosquito mortality following exposure to discriminating insecticide doses, identifying resistant populations but providing limited mechanistic information [49]. Synergist bioassays incorporating pre-exposure to piperonyl butoxide before pyrethroid testing enable differentiation between metabolic and target site resistance, as metabolically resistant mosquitoes demonstrate restored susceptibility following P450 inhibition, while those with target site mutations remain resistant [50].

Molecular diagnostics detecting knockdown resistance mutations through polymerase chain reaction assays provide definitive genotypic information regarding target site resistance. Quantitative gene expression analyses measuring cytochrome P450 transcript abundance identify populations with elevated metabolic enzyme expression, though transcript levels do not always correlate precisely with enzyme activity or resistance phenotypes [51]. Biochemical assays directly measuring P450 enzyme activity using model substrates like 7-ethoxycoumarin offer functional assessments of metabolic capacity, providing mechanistically relevant data for predicting piperonyl butoxide efficacy.

Integration of multiple diagnostic approaches generates comprehensive resistance profiles informing deployment strategies [52]. Populations exhibiting high P450 activity with moderate target site mutation frequencies represent ideal candidates for piperonyl butoxide net deployment, as the synergist addresses the predominant resistance mechanism [53]. Conversely, populations with high-frequency target site mutations and low P450 activity may derive limited benefit from synergist nets, warranting alternative interventions.

National Implementation Policies

National malaria control programs face strategic decisions regarding whether to deploy piperonyl butoxide nets universally, target them to high-resistance areas, or reserve them for specific epidemiological contexts [54]. Universal deployment simplifies logistics and ensures coverage in all areas, though it increases costs in settings where standard nets would perform adequately [55]. Targeted deployment based on resistance surveillance

<https://rijournals.com/biological-and-applied-science/>

optimizes cost effectiveness by concentrating synergist nets where they provide maximal added value, though it requires robust surveillance infrastructure and introduces supply chain complexity.

Several African countries have adopted phased approaches, initially deploying piperonyl butoxide nets in regions with documented high-intensity resistance while continuing standard nets elsewhere [56]. Burkina Faso, Uganda, and Tanzania have incorporated piperonyl butoxide nets into routine mass distribution campaigns, supported by national resistance monitoring systems tracking temporal and spatial resistance trends [57]. These implementation experiences provide valuable lessons regarding operational feasibility, community acceptance, and programmatic integration [58].

LIMITATIONS AND FUTURE DIRECTIONS

Resistance to Piperonyl Butoxide Synergism

Theoretical concerns exist regarding potential mosquito adaptation to piperonyl butoxide through mechanisms that circumvent P450 inhibition or through selection of piperonyl butoxide-insensitive P450 variants [59]. Laboratory selection experiments applying continuous pressure with piperonyl butoxide-pyrethroid combinations have generated populations showing reduced synergism, suggesting evolutionary potential for counter-adaptation [60]. However, field surveillance data from areas with multi-year piperonyl butoxide net deployment have not yet documented widespread emergence of synergist resistance, possibly reflecting fitness costs associated with counter-resistance mechanisms [61].

The biochemical diversity of cytochrome P450 enzymes provides potential pathways for resistance evolution through upregulation of P450 isoforms less sensitive to piperonyl butoxide inhibition or through structural mutations reducing inhibitor binding [62]. Monitoring programs should incorporate assessments of synergist efficacy over time, using bioassays that measure mosquito responses to piperonyl butoxide-pyrethroid combinations relative to pyrethroids alone [63].

Alternative Synergists and Novel Approaches

Research continues exploring alternative synergist compounds that might offer improved properties compared to piperonyl butoxide, including greater potency, enhanced durability, or activity against broader resistance mechanisms [64]. Diethyl maleate and triphenyl phosphate demonstrate synergistic activity in laboratory studies, though none have advanced to commercial net formulations [65]. Novel chemical scaffolds targeting specific cytochrome P450 active sites associated with pyrethroid metabolism represent promising research directions.

Integration of multiple insecticide classes with distinct modes of action, such as pyrrole or neonicotinoid compounds, provides alternative strategies for managing resistance without relying exclusively on synergists [66]. Nets incorporating multiple active ingredients from different chemical classes potentially delay resistance evolution by increasing the number of simultaneous adaptations required for survival [67]. However, regulatory pathways, manufacturing complexity, and cost considerations currently limit operational deployment of such products [68].

Integrated Resistance Management Frameworks

Sustainable vector control in the resistance era requires comprehensive strategies integrating multiple interventions rather than relying on single tools [69]. Piperonyl butoxide nets represent one component within broader frameworks incorporating indoor residual spraying with non-pyrethroid insecticides, larval source management, spatial repellents, and emerging technologies like attractive toxic sugar baits. Rotation strategies alternating between different insecticide classes and resistance management approaches aim to reduce selection pressure and preserve susceptibility [70].

Mathematical modeling studies suggest that judicious deployment of resistance management tools, informed by surveillance data and guided by evolutionary principles, can extend the operational lifespan of existing insecticides while maintaining transmission control [71]. These frameworks require sustained investment in surveillance infrastructure, operational research, and adaptive management systems capable of responding to evolving resistance profiles [72].

CONCLUSION

Pyrethroid resistance in Anopheles mosquito populations represents a formidable threat to malaria vector control efforts globally, driven predominantly by cytochrome P450-mediated metabolic detoxification alongside target site mutations in voltage-gated sodium channels. Piperonyl butoxide-treated insecticide nets provide an evidence-based countermeasure by inhibiting pyrethroid-metabolizing P450 enzymes through the formation of stable metabolic intermediate complexes, thereby restoring insecticide susceptibility in metabolically resistant populations. Large-scale field trials across multiple African settings demonstrate that synergist-treated nets deliver superior epidemiological protection compared to standard pyrethroid-only nets in areas with confirmed high-intensity metabolic resistance, reducing malaria prevalence and clinical incidence with acceptable cost-effectiveness profiles. Successful deployment requires integration of resistance surveillance systems capable of characterizing local resistance mechanisms, enabling targeted implementation strategies that optimize resource allocation. While piperonyl butoxide nets represent a valuable tool, they do not constitute a comprehensive solution to the resistance challenge. Limitations include potential for counter-resistance evolution, differential durability of synergist and

insecticide components, and reduced effectiveness against target site resistance mechanisms. The sustainability of vector control effectiveness demands comprehensive resistance management frameworks incorporating diverse interventions, insecticide rotation strategies, novel technologies, and adaptive implementation guided by ongoing surveillance. Future research should prioritize the development of next-generation synergists with enhanced potency against diverse cytochrome P450 isoforms and the investigation of multi-active ingredient net formulations that simultaneously address both metabolic and target site resistance mechanisms through complementary biochemical pathways.

REFERENCES

1. Egwu, C.O., Alope, C., Chukwu, J., Agwu, A., Alum, E.U, Tsamesidis, I, et al. A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. *Afr Health Sci.* 2022;22(4):627-640. doi: 10.4314/ahs.v22i4.68.
2. Tufail, T., Agu, P. C., Akinloye, D. I., & Obaroh, I. O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. *Medicine.* 2024;103(49), e40241. doi: 10.1097/MD.00000000000040241. PMID: 39654176
3. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature.* 2015;526(7572):207-211. DOI: 10.1038/nature15535
4. Ranson H, Lissenden N. Insecticide resistance in African *Anopheles* mosquitoes: a worsening situation that needs urgent action to maintain malaria control. *Trends in Parasitology.* 2016;32(3):187-196. DOI: 10.1016/j.pt.2015.11.010
5. Hemingway J, Ranson H, Magill A, Kolaczinski J, Fornadel C, Gimnig J, et al. Averting a malaria disaster: will insecticide resistance derail malaria control? *Lancet.* 2016;387(10029):1785-1788. DOI: 10.1016/S0140-6736(15)00417-1
6. Riveron JM, Tchouakui M, Mugenzi L, Menze BD, Chiang MC, Wondji CS. Insecticide resistance in malaria vectors: an update at a global scale. In: Manguin S, Dev V, editors. *Towards Malaria Elimination: A Leap Forward.* London: IntechOpen; 2018. p. 149-175. DOI: 10.5772/intechopen.78375
7. Strode C, Donegan S, Garner P, Enayati AA, Hemingway J. The impact of pyrethroid resistance on the efficacy of insecticide-treated bed nets against African anopheline mosquitoes: systematic review and meta-analysis. *PLoS Medicine.* 2014;11(3):e1001619. DOI: 10.1371/journal.pmed.1001619
8. Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, et al. Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. *Lancet.* 2018;391(10130):1577-1588. DOI: 10.1016/S0140-6736(18)30427-6
9. Alum EU. Phytochemicals in Malaria Treatment: Mechanisms of Action and Clinical Efficacy. *KIU J. Health Sci.*, 2024; 4(2):71-84. <https://doi.org/10.59568/KJHS-2024-4-2-06>.
10. Du Y, Nomura Y, Zhorov BS, Dong K. Sodium channel mutations and pyrethroid resistance in *Aedes aegypti*. *Insects.* 2016;7(4):60. DOI: 10.3390/insects7040060
11. Silver KS, Du Y, Nomura Y, Oliveira EE, Salgado VL, Zhorov BS, et al. Voltage-gated sodium channels as insecticide targets. *Advances in Insect Physiology.* 2014;46:389-433. DOI: 10.1016/B978-0-12-417010-0.00005-7
12. Donnelly MJ, Corbel V, Weetman D, Wilding CS, Williamson MS, Black WC. Does *kdr* genotype predict insecticide-resistance phenotype in mosquitoes? *Trends in Parasitology.* 2009;25(5):213-219. DOI: 10.1016/j.pt.2009.02.007
13. Jones CM, Liyanapathirana M, Agossa FR, Weetman D, Ranson H, Donnelly MJ, et al. Footprints of positive selection associated with a mutation (N1575Y) in the voltage-gated sodium channel of *Anopheles gambiae*. *Proceedings of the National Academy of Sciences USA.* 2012;109(17):6614-6619. DOI: 10.1073/pnas.1201475109
14. Rinkevich FD, Du Y, Dong K. Diversity and convergence of sodium channel mutations involved in resistance to pyrethroids. *Pesticide Biochemistry and Physiology.* 2013;106(3):93-100. DOI: 10.1016/j.pestbp.2013.02.007
15. Bagi J, Grisales N, Corkill R, Morgan JC, N'Fale S, Brogdon WG, et al. When a discriminating dose assay is not enough: measuring the intensity of insecticide resistance in malaria vectors. *Malaria Journal.* 2015;14:210. DOI: 10.1186/s12936-015-0721-4
16. Weetman D, Donnelly MJ. Evolution of insecticide resistance diagnostics in malaria vectors. *Transactions of the Royal Society of Tropical Medicine and Hygiene.* 2015;109(5):291-293. DOI: 10.1093/trstmh/trv017
17. Feyereisen R. Insect CYP genes and P450 enzymes. In: Gilbert LI, editor. *Insect Molecular Biology and Biochemistry.* London: Academic Press; 2012. p. 236-316. DOI: 10.1016/B978-0-12-384747-8.10008-X

18. Ortiz de Montellano PR. *Cytochrome P450: Structure, Mechanism, and Biochemistry*. 4th ed. New York: Springer; 2015. DOI: 10.1007/978-3-319-12108-6
19. Edi CV, Djogbenou L, Jenkins AM, Regna K, Muskavitch MAT, Poupardin R, et al. CYP6 P450 enzymes and ACE-1 duplication produce extreme and multiple insecticide resistance in the malaria mosquito *Anopheles gambiae*. *PLoS Genetics*. 2014;10(3):e1004236. DOI: 10.1371/journal.pgen.1004236
20. Stevenson BJ, Bibby J, Pignatelli P, Muangnoicharoen S, O'Neill PM, Lian LY, et al. Cytochrome P450 6M2 from the malaria vector *Anopheles gambiae* metabolizes pyrethroids: sequential metabolism of deltamethrin revealed. *Insect Biochemistry and Molecular Biology*. 2011;41(7):492-502. DOI: 10.1016/j.ibmb.2011.02.003
21. Pavlidi, N., Vontas, J., & Van Leeuwen, T. (2018). The role of glutathione S-transferases (GSTs) in insecticide resistance in crop pests and disease vectors. *Current opinion in insect science*, 27, 97-102.
22. Mitchell SN, Stevenson BJ, Muller P, Wilding CS, Egyir-Yawson A, Field SG, et al. Identification and validation of a gene causing cross-resistance between insecticide classes in *Anopheles gambiae* from Ghana. *Proceedings of the National Academy of Sciences USA*. 2012;109(16):6147-6152. DOI: 10.1073/pnas.1203452109
23. Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. *INOSR Scientific Research*. 2024; 11(2):16-22. <https://doi.org/10.59298/INOSRSR/2024/1.1.21622>
24. Rock, D., Schrag, M., & Wienkers, L. C.: Experimental Characterization of Cytochrome P450 Mechanism-Based Inhibition. In *Handbook of Drug Metabolism, Third Edition* 2019. pp. 523-547. CRC Press.
25. Balabanidou V, Grigoraki L, Vontas J. Insect cuticle: a critical determinant of insecticide resistance. *Current Opinion in Insect Science*. 2018;27:68-74. DOI: 10.1016/j.cois.2018.03.001
26. Gleadow RM, Møller BL. Cyanogenic glycosides: synthesis, physiology, and phenotypic plasticity. *Annual Review of Plant Biology*. 2014;65:155-185. DOI: 10.1146/annurev-arplant-050213-040027
27. Yunta C, Grisales N, Nász S, Hemmings K, Pignatelli P, Voice M, et al. Pyriproxyfen is metabolized by P450s associated with pyrethroid resistance in *An. gambiae*. *Insect Biochemistry and Molecular Biology*. 2016;78:50-57. DOI: 10.1016/j.ibmb.2016.09.001
28. Pennetier C, Bouraima A, Chandre F, Pameu M, Etang J, Rossignol M, et al. Efficacy of Olyset® Plus, a new long-lasting insecticidal net incorporating permethrin and piperonyl butoxide against multi-resistant malaria vectors. *PLoS One*. 2013;8(10):e75134. DOI: 10.1371/journal.pone.0075134
29. Gleave K, Lissenden N, Chaplin M, Choi L, Ranson H. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. *Cochrane Database of Systematic Reviews*. 2021;5(5):CD012776. DOI: 10.1002/14651858.CD012776.pub3
30. Oxborough RM, N'Guessan R, Jones R, Kitau J, Ngufor C, Malone D, et al. The activity of the pyrrole insecticide chlorfenapyr in mosquito bioassay: towards a more rational testing and screening of non-neurotoxic insecticides for malaria vector control. *Malaria Journal*. 2015;14:124. DOI: 10.1186/s12936-015-0639-x
31. Staedke SG, Gonahasa S, Dorsey G, Kanya MR, Maiteki-Sebuguzi C, Lynd A, et al. Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign. *Lancet*. 2020;395(10232):1292-1303. DOI: 10.1016/S0140-6736(20)30214-2
32. Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, et al. Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. *Lancet*. 2018;391(10130):1577-1588. DOI: 10.1016/S0140-6736(18)30427-6
33. Kleinschmidt I, Bradley J, Knox TB, Mnzava AP, Kafy HT, Mbogo C, et al. Implications of insecticide resistance for malaria vector control with long-lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study. *Lancet Infectious Diseases*. 2018;18(6):640-649. DOI: 10.1016/S1473-3099(18)30172-5
34. Staedke SG, Gonahasa S, Dorsey G, Kanya MR, Maiteki-Sebuguzi C, Lynd A, et al. Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national LLIN distribution campaign. *Lancet Infectious Diseases*. 2020;20(10):1179-1191. DOI: 10.1016/S1473-3099(20)30214-2
35. Churcher TS, Lissenden N, Griffin JT, Worrall E, Ranson H. The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. *eLife*. 2016;5:e16090. DOI: 10.7554/eLife.16090

36. Mosha JF, Kulkarni MA, Lukole E, Matowo NS, Pitt C, Messenger LA, et al. Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised trial. *Lancet*. 2022;399(10331):1227-1241. DOI: 10.1016/S0140-6736(21)02499-5
37. N'Guessan R, Odjo A, Ngufor C, Malone D, Rowland M. A chlorfenapyr mixture net Interceptor® G2 shows high efficacy and wash durability against resistant mosquitoes in West Africa. *PLoS One*. 2016;11(11):e0165925. DOI: 10.1371/journal.pone.0165925
38. Corbel V, N'Guessan R. Distribution, mechanisms, impact and management of insecticide resistance in malaria vectors: a pragmatic review. In: *Anopheles mosquitoes: New insights into malaria vectors*. London: IntechOpen; 2013. p. 579-633. DOI: 10.5772/56117
39. WHO Pesticide Evaluation Scheme. Guidelines for Laboratory and Field Testing of Long-Lasting Insecticidal Nets. Geneva: World Health Organization; 2013. WHO/HTM/NTD/WHOPES/2013.3
40. Snetselaar J, Rowland MW, Manunda BJ, Kisengwa ER, Drakeley CJ, Malima RC, et al. Efficacy of improved dual-active ingredient long-lasting insecticidal nets compared to standard LLINs against pyrethroid-resistant *Anopheles gambiae*: results from experimental hut trials in Tanzania. *Malaria Journal*. 2021;20:484. DOI: 10.1186/s12936-021-04019-8
41. Tungu P, Magesa S, Maxwell C, Malima R, Masue D, Sudi W, et al. Evaluation of PermaNet 3.0 a deltamethrin-PBO combination net against *Anopheles gambiae* and pyrethroid resistant *Culex quinquefasciatus* mosquitoes: an experimental hut trial in Tanzania. *Malaria Journal*. 2010;9:21. DOI: 10.1186/1475-2875-9-21
42. Ngufor C, N'Guessan R, Boko P, Odjo A, Vigninou E, Asidi A, et al. Combining indoor residual spraying with chlorfenapyr and long-lasting insecticidal bed nets for improved control of pyrethroid-resistant *Anopheles gambiae*: an experimental hut trial in Benin. *Malaria Journal*. 2011;10:343. DOI: 10.1186/1475-2875-10-343
43. Winskill P, Walker PGT, Griffin JT, Ghani AC. Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa. *BMJ Global Health*. 2017;2(1):e000090. DOI: 10.1136/bmjgh-2016-000090
44. Hemingway J. The role of vector control in stopping the transmission of malaria: threats and opportunities. *Philosophical Transactions of the Royal Society B: Biological Sciences*. 2014;369(1645):20130431. DOI: 10.1098/rstb.2013.0431
45. Protopopoff N, Wright A, West PA, Tigrero-Barrera M, Mosha FW, Kisinza W, et al. Combination of insecticide resistance mechanisms in *Anopheles gambiae* from Experimental Hut trials in Tanzania. *Malaria Journal*. 2015;14:470. DOI: 10.1186/s12936-015-1004-x
46. Killeen GF, Ranson H. Insecticide-resistant malaria vectors must be tackled. *Lancet*. 2018;391(10130):1551-1552. DOI: 10.1016/S0140-6736(18)30844-4
47. Toe KH, Jones CM, N'Fale S, Ismail HM, Dabiré RK, Ranson H. Increased pyrethroid resistance in malaria vectors and decreased bed net effectiveness, Burkina Faso. *Emerging Infectious Diseases*. 2014;20(10):1691-1696. DOI: 10.3201/eid2010.140619
48. Oxborough RM. Trends in US President's Malaria Initiative-funded indoor residual spray coverage and insecticide choice in sub-Saharan Africa (2008-2015): urgent need for affordable, long-lasting insecticides. *Malaria Journal*. 2016;15:146. DOI: 10.1186/s12936-016-1201-1
49. WHO Global Malaria Programme. Global Plan for Insecticide Resistance Management in Malaria Vectors. Geneva: World Health Organization; 2012. ISBN: 9789241564472
50. Balabanidou V, Kampouraki A, MacLean M, Blomquist GJ, Tittiger C, Juárez MP, et al. Cytochrome P450 associated with insecticide resistance catalyzes cuticular hydrocarbon production in *Anopheles gambiae*. *Proceedings of the National Academy of Sciences USA*. 2016;113(33):9268-9273. DOI: 10.1073/pnas.1608295113
51. Vontas J, Kioulos E, Pavlidi N, Morou E, della Torre A, Ranson H. Insecticide resistance in the major dengue vectors *Aedes albopictus* and *Aedes aegypti*. *Pesticide Biochemistry and Physiology*. 2012;104(2):126-131. DOI: 10.1016/j.pestbp.2012.05.008
52. Djouaka R, Riveron JM, Yessoufou A, Tchigossou G, Akoton R, Irving H, et al. Multiple insecticide resistance in an infected population of the malaria vector *Anopheles funestus* in Benin. *Parasites & Vectors*. 2016;9:453. DOI: 10.1186/s13071-016-1723-y
53. Ndiath MO, Cailleau A, Diedhiou SM, Gaye A, Boudin C, Richard V, et al. Effects of the kdr resistance mutation on the susceptibility of wild *Anopheles gambiae* populations to *Plasmodium falciparum*: a hindrance for vector control. *Malaria Journal*. 2014;13:340. DOI: 10.1186/1475-2875-13-340
54. Kawada H, Ohashi K, Dida GO, Sonye G, Njenga SM, Mwandawiro C, et al. Preventive effect of permethrin-impregnated long-lasting insecticidal nets on the blood feeding of three major pyrethroid-

- resistant malaria vectors in western Kenya. *Parasites & Vectors*. 2014;7:383. DOI: 10.1186/1756-3305-7-383
55. World Health Organization. Conditions for deployment of mosquito nets treated with a pyrethroid and piperonyl butoxide. Geneva: World Health Organization; 2017. WHO/HTM/GMP/2017.17
 56. Badolo A, Traore A, Jones CM, Sanou A, Flood L, Guelbeogo WM, et al. Three years of insecticide resistance monitoring in *Anopheles gambiae* in Burkina Faso: resistance on the rise? *Malaria Journal*. 2012;11:232. DOI: 10.1186/1475-2875-11-232
 57. Corbel V, Chabi J, Dabiré RK, Etang J, Nwane P, Pigeon O, et al. Field efficacy of a new mosaic long-lasting mosquito net (PermaNet 3.0) against pyrethroid-resistant malaria vectors: a multi centre study in Western and Central Africa. *Malaria Journal*. 2010;9:113. DOI: 10.1186/1475-2875-9-113
 58. Tiono AB, Ouedraogo A, Ogutu B, Diarra A, Coulibaly S, Gansané A, et al. Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. *Lancet*. 2018;392(10147):569-580. DOI: 10.1016/S0140-6736(18)31711-2
 59. Tchouakui M, Chiang MC, Ndo C, Kuicheu CK, Amvongo-Adjia N, Wondji MJ, et al. A marker of glutathione S-transferase-mediated resistance to insecticides is associated with higher *Plasmodium* infection in the African malaria vector *Anopheles funestus*. *Scientific Reports*. 2019;9:5772. DOI: 10.1038/s41598-019-42015-1
 60. Ffrench-Constant RH, Bass C. Does resistance really carry a fitness cost? *Current Opinion in Insect Science*. 2017;21:39-46. DOI: 10.1016/j.cois.2017.04.011
 61. Riveron JM, Yunta C, Ibrahim SS, Djouaka R, Irving H, Menze BD, et al. A single mutation in the *GSTe2* gene allows tracking of metabolically based insecticide resistance in a major malaria vector. *Genome Biology*. 2014;15(2):R27. DOI: 10.1186/gb-2014-15-2-r27
 62. Dagg K, Irish S, Wiegand RE, Shililu J, Yewhalaw D, Messenger LA. Evaluation of toxicity of clothianidin (neonicotinoid) and chlorfenapyr (pyrrole) insecticides and cross-resistance to other public health insecticides in *Anopheles arabiensis* from Ethiopia. *Malaria Journal*. 2019;18:49. DOI: 10.1186/s12936-019-2685-2
 63. Saavedra-Rodriguez K, Maloof N, Campbell CL, Garcia-Rejon J, Lenhart A, Penilla P, et al. Parallel evolution of *vpsc* mutations at domains IS6, IIS6 and IIS6 in pyrethroid resistant *Aedes aegypti* from Mexico. *Scientific Reports*. 2018;8:6747. DOI: 10.1038/s41598-018-25222-0
 64. Carrasco D, Lefèvre T, Moiroux N, Pennetier C, Chandre F, Cohuet A. Behavioural adaptations of mosquito vectors to insecticide control. *Current Opinion in Insect Science*. 2019;34:48-54. DOI: 10.1016/j.cois.2019.03.005
 65. Nauen R, Slater R, Sparks TC, Elbert A, Crossthwaite A. IRAC: Insecticide resistance and mode-of-action classification of insecticides. In: Krämer W, Schirmer U, editors. *Modern Crop Protection Compounds*. 2nd ed. Weinheim: Wiley-VCH; 2012. p. 935-955. DOI: 10.1002/9783527644179.ch30
 66. Oliver SV, Brooke BD. The role of oxidative stress in the longevity and insecticide resistance phenotype of the major malaria vectors *Anopheles arabiensis* and *Anopheles funestus*. *PLoS One*. 2016;11(3):e0151049. DOI: 10.1371/journal.pone.0151049
 67. Ainebyoona C, Egwu CO, Onohuean H, Ugwu OP, Uti DE, Echegu DA. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication. *Ethiop J Health Sci*. 2025 May;35(3):205-217. doi: 10.4314/ejhs.v35i3.9. PMID: 40717722; PMCID: PMC12287706.
 68. Mezieobi KC, Alum EU, Ugwu OP, Uti DE, Alum BN, Egba SI, Ewah CM. Economic burden of malaria on developing countries: A mini review. *Parasite Epidemiol Control*. 2025 May 29;30:e00435. doi: 10.1016/j.parepi.2025.e00435. PMID: 40519859; PMCID: PMC12163157.
 69. Messenger LA, Matias A, Manana AN, Stiles-Ocran JB, Knowles S, Boakye DA, et al. Multicentre studies of insecticide-treated durable wall lining in Africa and South-East Asia: entomological efficacy and household acceptability during one year of field use. *Malaria Journal*. 2012;11:358. DOI: 10.1186/1475-2875-11-358
 70. malERA Consultative Group on Vector Control. A research agenda for malaria eradication: vector control. *PLoS Medicine*. 2011;8(1):e1000401. DOI: 10.1371/journal.pmed.1000401
 71. Ranson H, Lissenden N. Insecticide resistance in African *Anopheles* mosquitoes: a worsening situation that needs urgent action to maintain malaria control. *Trends in Parasitology*. 2016;32(3):187-196. DOI: 10.1016/j.pt.2015.11.010
 72. Okumu FO, Moore SJ. Combining indoor residual spraying and insecticide-treated nets for malaria control in Africa: a review of possible outcomes and an outline of suggestions for the future. *Malaria Journal*. 2011;10:208. DOI: 10.1186/1475-2875-10-208